Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma - Fuji - Stem Cell Investigation
Mogamulizumab in Adult T-Cell Leukemia/Lymphoma | SpringerLink
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment - ScienceDirect
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions | Cancer Immunology Research
Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome - JAAD Case Reports
Elotuzumab mechanism of action. The primary mechanism of action of... | Download Scientific Diagram
Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram
Imugene' in Immunology and Biotherapies | Scoop.it
JCM | Free Full-Text | NK Cell-Fc Receptors Advance Tumor Immunotherapy | HTML
Mogamulizumab Overview - Creative Biolabs
Sanofi turns to Innate Pharma for new antibody ...
Novel targeted therapies of T cell lymphomas | Journal of Hematology & Oncology | Full Text
Mogamulizumab
POTELIGEO, INN-mogamulizumab
Poteligeo HCP - Mechanism of action
The peripheral T-cell lymphomas: an unusual path to cure - The Lancet Haematology
HDAC mechanism of action. Abbreviations: HDAC, histone deacetylase;... | Download Scientific Diagram
Lead team presentation
The landscape of new drugs in extranodal NK/T-cell lymphoma - Cancer Treatment Reviews
CCR4 Antagonists Inhibit T<sub>reg</sub> Trafficking into the Tumor Microenvironment. - Abstract - Europe PMC
Biomarker-driven management strategies for peripheral T cell lymphoma | Journal of Hematology & Oncology | Full Text
Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment
Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem | Clinical Cancer Research
